Doesn't matter, Pfizer is clearly working off their valuation so...

First 429 Last

Share
Profile

Follow
AlCp

26,688 Posts.

1732

11/08/22

12:50

Post #: 63055438
Share

Originally posted by pilko3 ↑

Who knows what influences were brought to the attention of the so called Independent Valuer prior to their appointment and or report. Whoa actually gave them the estimated figures of use/uptake that they used in order to give some of their revenue/earnings estimates. It is this that stands out for me.
Not suggesting that the IE was "got at" not at all. However if that IE relied on information from RAP re marketing/sales/assumed usage results and they were given the only figures available as a guide..for a one sided perspective these figures would far from reflect the ongoing potential or reality of the future as these figures would be based on absolute minimums due to the fact they were most likely gleaned from the first TH platforms trying out DX. The first platforms were almost fishing in the dark and were still experimenting trying out the tech...hardly a basis for any credible projections of future uptake.
So IE by fair means or via some of the first Ozzie Telehealth (Covui ?) attempts could have arrived at these low ball values and so set the stage for Pfizer to offer such low prices...whilst remaining within the IE guidelines. How convenient!
The stage is set...the first song has been sung...but the Oprey ain't over until the Phat Lady sings. IMHO she hasn't even begun to warble or even warm up her vocal chords! It is NO and thus it shall be...from little things big things grow!

Expand

Doesn't matter, Pfizer is clearly working off their valuation so there is no way they will offer 40-50c, let alone the insane $1 some has been saying.

RAP Price at posting: 19.3¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

RCE

Recce's R327 found effective against E.coli during clinical trial

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Microcap Wrap: 5 explorers with news out today

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

There are more pages in this discussion • 38 more messages in this thread...

First 429 Last

Add RAP (ASX) to my watchlist

Doesn't matter, Pfizer is clearly working off their valuation so...

Top Stories

Ava Risk Group expands US presence with A$0.7M Substation Deal

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Recce's R327 found effective against E.coli during clinical trial

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Microcap Wrap: 5 explorers with news out today

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Featured News